检索结果-南通市图书馆

Comparative Efficacy and Safety of Biological Drugs in Ankylosing Spondylitis:a Multiple-treatment Meta-analysis

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Comparative Efficacy and Safety of Biological Drugs in Ankyl...

2016全国药物流行病学学术年会

作者： Zhang Xu Pan Faming Department of Epidemiology and Biostatistics School of Public HealthAnhui Medical University

Objectives:Conventional analyses have shown biological drugs were more effective than placebo for ankylosing spondylitis（AS）,but have not attempted to rank the effectiveness of *** did a multiple-treatment meta-analysis,which accounted for both direct and indirect comparisons,to assess the efficacy and safety of these biological ***:We systematically reviewed 27 randomized controlled trials（4 429 participants） from 2002 to 2015,which compared 8 biological drugs for treatment of ankylosing *** main assessment criteria was the percentage of patients with a 20% response according to the assessment of Spondylo Arthritis international Society criteria for improvement（ASAS20） and the number of patients who was reported the treatment-emergent adverse events（AEs） or serious adverse events（SAEs） at 12 *** was done on an intention-to-treat ***:Certolizumab pegol（odds ratios [OR] 2.63 [95%CI 1.12 to 6.16]）,etanercept（3.20 [1.71 to 5.98]）,glolimumab（5.07 [2.58 to 9.98]）,infliximab（5.28 [2.61 to 10.65]）,secukinumab（7.78 [1.43 to 42.23]）,adalimumab（4.39 [1.98 to 9.74]）,and CT-P13（4.76 [1.55 to 14.56]） were all significantly more effective than placebo,whereas tocilizumab was not;among the 7 effective biological drugs,their efficacy and safety have no significant *** compared with placebo,etanercept（2.06 [1.08 to 3.64]） and adalimumab（3.01 [1.12 to 6.50]） tend to have more AEs and infliximab（3.10 [1.10 to 7.29]） has more ***:Overall,biological drugs were significantly more effective than placebo,with the exception of *** these drugs have similar efficacy,we suggest glolimumab and adalimumab were safer among them.

关键词： Ankylosing spondylitis Biological drugs Multiple-treatment Network Meta-analysis

Quality Assessment of Clinical Practice Guidelines on Tic Disorders with AGREE Ⅱ Instrument

在线全文

cnki会议

学校读者我要写书评

暂无评论

Quality Assessment of Clinical Practice Guidelines on Tic Di...

2016全国药物流行病学学术年会

作者： Yang Chunsong Zhang Zuojie Zhang Lingli Tian Jinhui Yu Dan Wang Jingjing Yang Jing Department of Pharmacy Evidence-based Pharmacy CenterWest China second hospitalSichuan University Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) Ministry of Education West China School of Pharmacy Sichuan University Department of Pediatric Neurology West China HospitalSichuan University Evidence-based Medicine Center School of Basic Medical SciencesLanzhou University The Fourth People's Hospital of Chengdu

Objective:To assess the methodological quality existing clinical practice guidelines（CPGs） on the treatment of tic disorders（TDs） and summarize recommendations in these ***:The CPGs on the treatment of TDs in seven databases were searched *** of Guidelines for Research ＆ Evaluation II（AGREE II） instrument was used to assess the quality of these included ***:Five CPGs meeting our inclusion criteria were *** mean percentage of the domain scores were as follows:scope and purpose 83.33%（95% CI,77.78%- 94.44%）,stakeholder involvement 62.22%（95% CI,38.89%- 94.44%）,rigour of development 47.08%（95% CI,6.25%- 83.33%）,clarity of presentation 87.78 %（95% CI,72.22%- 94.44%）,applicability 56.67%（95% CI,33.33%- 87.50%）,editorial independence 46.67%（95% CI,8.33%- 91.67%）.Large differences existed among these 5 CPGs concerning the categorization of evidence and recommendations,however the recommendations of drug therapy in five CPGs were basically the same,with some controversy in certain ***:The methodological quality of CPGs for TDs is acceptable for scope,purpose stakeholder involvement and clarity of *** developers of CPGs need to pay more attention to rigour of development,applicability and editorial *** guideline developers should improve adherence to the AGREE II guidelines and high quality studies for the treatment of TDs is needed.

关键词： Tic disorders Clinical practice guidelines AGREE Ⅱ

Prevalence of Tic Disorders for children in China:A Systematic Review and Meta Analysis

在线全文

cnki会议

学校读者我要写书评

暂无评论

Prevalence of Tic Disorders for children in China:A Systemat...

2016全国药物流行病学学术年会

作者： Yang Chunsong Zhang Lingli Zhu Ping Zhu Cairong Guo Qin Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalKey Laboratory of Birth Defects and Related Diseases of Women and ChildrenSichuan University West China School of Public Health Sichuan University Department of Pediatrics West China second hospitalKey Laboratory of Birth Defects and Related Diseases of Women and ChildrenSichuan University

Objective:To depict the prevalence of Tic disorders（TD） for children in China and explore the influence of sex,age,geographic distribution and diagnostic criteria on the prevalence ***:We searched Pub Med,EMBASE,four Chinese electronic databases and relevant reference *** reviewers independently selected trials,assessed trial quality,and extracted the ***:We included 13 studies investigating 269 571 *** sample size ranged from 563 to 216 005 *** age of participants ranged from 3 to 16 *** Meta analysis of the prevalence of TD was 6.1%（95%CI:0.036-0.100,I2=49.7%）.The prevalence of transient tic disorder（TTD）,chronic tic disorder（CTD） and Tourette syndrome（TS） were 1.7%（95%CI:0.009-0.031,I2=49%）,1.2%（95%CI:0.007-0.022,I2=48.3%） and 0.3%（95%CI:0.001-0.008,I2=49.5%） *** prevalence of TD in boys（5.1%,95%CI:0.026-0.098,I2=49.3%） was higher than that in girls（2.4%,95%CI:0.009-0.065,I2=49.4%）.The prevalence of TD in urban（2.6%,95%CI:0.019-0.034,I2=35.5%） was higher than that in rural area（2.2%,95%CI:0.016-0.030,I2=33.9%）.The prevalence of TD in central China（10.7%,95%CI:0.043-0.242,I2=49.2%） was higher than that in North China（7.8%,95%CI:0.007-0.522,I2=49.9%） and East China（4.4%,95%CI:0.015-0.120,I2=49.8%）.Conclusions:TD is a common disease in China,with prevalence differing based on sex,age,and region.

关键词： Tic disorders Children Prevalence Meta analysis China

Trends and Quality Assessment of RCTs for Tic Disorders Published in China’s mainland

在线全文

cnki会议

学校读者我要写书评

暂无评论

Trends and Quality Assessment of RCTs for Tic Disorders Publ...

2016全国药物流行病学学术年会

作者： Yang Chunsong Wang Pingping Zhang Lingli Tian Jinhui Yu Dan Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan University Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) Ministry of Education The 181st Hospital of People’s Liberation Army Evidence-based Medicine Center School of Basic Medical SciencesLanzhou University Department of Pediatric Neurology West China HospitalSichuan University

Objective:Tic disorders（TDs）,are common neuropsychiatric disorders among children and adolescents,pharmacotherapy is the main management for TDs,with the introduction and development of evidence-based medicine in China,more and more RCTs have been carried out to evaluate the efficacy of many drugs for TDs,we aimed to evaluate the quantitative trends and quality indicators of RCTs published in China’s mainland,and provide scientific basis for future clinical ***:A comprehensive and systematic literature search was carried out for all RCTs related to drug therapy for *** Pub Med,EMBASE,and four chinese Database were *** quality was evaluated according to the Cochrane quality assessment ***:A total of 84 RCTs were included.4.8%（4/84） of RCTs included multiple-center *** study sample size ranged from 24 to 437（median 69 participants）.45.2%（38/84） of included RCTs evaluated the efficacy of atypical antipsychotic agonists,28.6%（24/84） assessed the efficacy of antiepileptic drugs,14.3%（12/84） evaluated the efficacy of typical antipsychotic agonists,6%（5/84） of RCTs assessed the efficacy of alpha-2adrenergic *** 3.6%（3/84） of RCTs were placebo control,and 96.4%（81/84） were positive drug control.20.3%（17/84） of RCTs used adequate method of random sequence *** 3.6%（3/84） of RCTs reported a reasonable allocation concealment,including a central allocation and sealed opaque envelopes.7.1%（6/84） of RCTs denoted blinding methods（double-blind for participants and investigators）.Conclusions:In the recent years,the growth of quantity of RCTs for TDs is not obvious,and the high-quality RCTs are *** RCTs for typical antipsychotic agonists（i.e,risperidone,aripiprazole,quetiapine）,antiepileptic drugs（i.e.,topiramate） are research *** future TDs trials should pay more attention to true randomization,allocation concealment,blinding and better patient outcome measures.

关键词： Tic disorders Drugs Randomized controlled trials Quality assessment

2006年(第六届)中国药学会学术年会的第二轮通知

在线全文

cnki会议

学校读者我要写书评

暂无评论

药物流行病学杂志 2006年第3期15卷 145-145页

由中国药学会主办、广东普乐康药业有限公司协办的2006年(第六届)中国药学会学术年会,定于2006年10月9日至13日在广东省广州市举行。本届年会是中国药学会贯彻落实中国科协七大和全国科学技术大会精神的一次会议,也是2007年中国药学会... 详细信息

由中国药学会主办、广东普乐康药业有限公司协办的2006年(第六届)中国药学会学术年会,定于2006年10月9日至13日在广东省广州市举行。本届年会是中国药学会贯彻落实中国科协七大和全国科学技术大会精神的一次会议,也是2007年中国药学会百年庆典、中国药学会第22次全国会员代表大会、国际药学联合会(FIP)

关键词：中国药学会学术年会

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

抗癫痫中成药临床应用的问题与挑战

抗癫痫中成药临床应用的问题与挑战

2012年浙江省神经病学学术年会

作者：郑荣远徐惠琴李进军王怡张秀华温州医学院附属第一医院神经科温州医学院公共卫生学院温州医学院附属第一医院药剂科

目的评价我国抗癫痫中成药临床应用的合理性与合法性,阐明我国抗癫痫中成药市场流通中存在的问题与及其再评价、市场监管面临的严重问题与挑战。方法采用系统评价方法,从中文生物医药文献数据库中全面搜索相关文献,结合10年来我院癫痫...

目的评价我国抗癫痫中成药临床应用的合理性与合法性,阐明我国抗癫痫中成药市场流通中存在的问题与及其再评价、市场监管面临的严重问题与挑战。方法采用系统评价方法,从中文生物医药文献数据库中全面搜索相关文献,结合10年来我院癫痫专病门诊中收集的有关资料),筛查出我国抗癫痫中成药名单及其市场流通状况;综合评价我国抗癫痫中成药临床应用的合理性;再从SFDA网站(国家批准市场流通)药品数据库中逐一核查"抗癫痫中成药名单"中所有药品的资料、结合患者血药浓度与药品化学成分检测结果,综合评判这些药品的合法性。结果与讨论:调查研究发现①在市场上合法流通的抗癫痫中成药仅占10%-17.0%,其余的均属于非法上市流通:②缺乏上市后监管措施:无批准文号的占12.4%,绝大部分是获批准文号上市的"假冒纯中药",隐瞒了掺合抗癫痫西药的事实,也属非法制药,打击乏力;③多级药品审批权限,批准文号混乱;④说明书不规范,审批松懈等;⑤是全国普遍存在的药政管理问题。⑥建议政府加强药政管理、对我国抗癫痫中成药市场要进行全面的整顿,实行产品成分检测、打击与废除假药劣药制造商、鼓励合法的抗癫痫中成药在市场上合理地流通。结论我国抗癫痫中成药上市后再评价、临床使用、市场药品监管所面临的严峻问题与挑战。尽快实施抗癫痫中成药的药政管理措施,倡导市场合法流通,是中国药物流行病学研究以及药政管理的重要课题,势在必行,造福病人。

关键词：

2011年全国医院药学学术年会暨第71届世界药学大会卫星会第一轮征文通知

在线全文

cnki会议

学校读者我要写书评

暂无评论

中国医院药学杂志 2011年第18期31卷 1569-1569页

为了学习和贯彻"国家“十二五”规划"中关于医疗卫生改革的要求,建立和完善以国家基本药物制度为基础的药品供应保障体系,确保药品质量和安全;探讨医院药学发展的新思维及发展中出现的新问题,分享新成果、新技术,推动我国医院药学事业... 详细信息

为了学习和贯彻"国家“十二五”规划"中关于医疗卫生改革的要求,建立和完善以国家基本药物制度为基础的药品供应保障体系,确保药品质量和安全;探讨医院药学发展的新思维及发展中出现的新问题,分享新成果、新技术,推动我国医院药学事业的和谐发展。经中国药学会批准,由中国药学会医院药学专业委员会主办"2011年全国医院药学学术年会暨第71届世界药学大会卫星会"拟于2011年10月举行,同期举行2011年度阿斯利康中国医院药学奖颁奖活动。大会第二天的卫星会将传达第71届世界药学大会的精彩内容,分享在药学教育、药事管理、临床生物、社区药学、医院药学、生物等效性、生物药学技术、药物流行病学和药物经济学、个体化药物、天然药物等方面的最新信息;该会议主题为"药物安全与疗效的妥协"。现面向全国医院药师、社会药师及医药相关领域人员征文。

关键词：医院药学学术年会中国药学会卫星

关于举办2006年(第六届)中国药学会学术年会的通知(第一轮)

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

药物流行病学杂志 2006年第1期15卷 58-58页

各有关单位: 中国药学会学术年会已经成功举办了五届,产生了重大影响,也得到广大会员和医药科技工作者的广泛支持和参与。 2006年(第六届)中国药学会学术年会定于2006年第三季度举行(地点见第二轮通知)。大会主题是:医药自主创新与可持... 详细信息

各有关单位: 中国药学会学术年会已经成功举办了五届,产生了重大影响,也得到广大会员和医药科技工作者的广泛支持和参与。 2006年(第六届)中国药学会学术年会定于2006年第三季度举行(地点见第二轮通知)。大会主题是:医药自主创新与可持续发展。会议将通过对中药和天然药物等十五个专业领域百年发展历史(特别是新中国成立和改革开放以采)的回顾,提出我国药学领域科技发展的重大问题,并进行广泛深入的学术交流与研讨;全面分析研究药学学科发展前景,提出药学各分支学科发展规划、趋势和建议,为我国药学科技发展勾画蓝图。本届年会将邀请我国医药卫生领域院士、政府部门领导、药学专家等做主会场大会报告,并进行多个分会场专题学术交流。

关键词：中国药学会天然药物中药学术年会